SCHEMBL3101384

SCHEMBL3101384

COc1ccc(Cn2nc(-c3ccc(C(=O)N4CCOCC4)cc3)c3c(Oc4ccc(-c5cnc(Nc6ccccc6)n(C)c5=O)cc4F)ccnc32)cc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 19/20 0.53
MST1R Q04912 6/20 0.48
KDR P35968 4/20 0.48
HGF P14210 4/20 0.48
RPS6KB1 P23443 3/20 0.48
TEK Q02763 3/20 0.48
BTK Q06187 3/20 0.48
EGFR P00533 2/20 0.48
FLT4 P35916 2/20 0.48
JAK2 O60674 1/20 0.48
FLT1 P17948 1/20 0.48
FGFR2 P21802 1/20 0.48
AURKA O14965 2/20 0.42
LCK P06239 2/20 0.42
CSF1R P07333 1/20 0.42
KCNK3 O14649 1/20 0.39
RPS6KA5 O75582 1/20 0.38
PIM1 P11309 1/20 0.38
MAPK9 P45984 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3109858 0.88 MET (0.58) METMST1RKDRHGFRPS6KB1
SCHEMBL3109872 0.85 MET (0.43) METMST1RKDRHGFRPS6KB1
SCHEMBL3109429 0.84 MET (0.60) METMST1RKDRHGFRPS6KB1
SCHEMBL3106815 0.83 MET (0.59) METMST1RKDRHGFRPS6KB1
SCHEMBL3104694 0.82 MET (0.55) METMST1RKDRHGFRPS6KB1
SCHEMBL3112956 0.82 SMN1; SMN2 (0.44) JAK2KCNK3
SCHEMBL3112398 0.79 MET (0.60) METMST1RKDRHGFRPS6KB1
SCHEMBL2285261 0.78 MET (0.58) METMST1RKDRHGFRPS6KB1
SCHEMBL3101359 0.77 AXL (0.50) MET
SCHEMBL3107753 0.74 KCNK3 (0.39) METMST1RKDRRPS6KB1TEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ARRAY BIOPHARMA INC. (US) 2010-10-07 US disclosed
US-7723330-B2 Heterobicyclic pyrazole compounds and methods of use ARRAY BIOPHARMA INC. (US) 2010-05-25 US disclosed
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use GENENTECH, INC. 2007-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256356-A1 HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE ROR1, CYP11B1, CYP11B2 MET 357/4885MST1R 642/4885KDR 807/4885
US-20070238726-A1 Heterobicyclic pyrazole compounds and methods of use ROR1, CYP11B1, CYP11B2 MET 357/4885MST1R 642/4885KDR 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.